Xu J, et al. - Researchers tested the combination of gemcitabine and docetaxel (GT) in patients with refractory metastatic osteosarcoma (OS), focusing on the efficacy and tolerability of the GT regimen. Patients with refractory metastatic osteosarcoma at Peking University People’s Hospital were retrospectively examined. These patients received gemcitabine (1,000 mg/m²) intravenously on Day 1 and Day 8, and docetaxel (75 mg/m²) IV on Day 8, repeated every 21 days. Findings revealed good tolerability of GT as a salvage regimen, but it was not as effective as expected, with an objective response rate (ORR) of 0%, a disease control rate of 9.6%, and a median duration of response of 3.5 months. In 69 (39.7%) courses and in 28 (53.8%) patients, grade 3 or 4 toxicities were seen, most of which were myelosuppression, especially thrombocytopenia. There was no fatal adverse effect. Findings call for the development of new approaches with higher activity in these patients.